Senior Research Fellow / September, 2002 — December, 2016

Principal Investigator overseeing assay development, in vitro pharmacology and animal studies on multiple drug discovery projects. Directed development and implementation of cell proliferation, differentiation and apoptosis assays for oncology and immunology projects, functional assays and target engagement studies in tissues, plasma, primary human and rodent cells. • Designed and managed various studies conducted by the CROs and academic groups including efficacy studies in rodents and Cynomolgus monkeys, DNA microarray and RNA-Seq differential gene expression analysis studies, PK, tissue distribution, DDI and off-target activity assays. • Contributed to the IND filing of several clinical candidates, prepared IND-enabling documents using submission authoring templates StartingPoint (Accenture). Conducted preliminary analysis of clinical results from the Psoriasis (RORγt inverse agonist) and Atopic Dermatitis (LXR agonist) trials.

Senior Research Scientist / February, 2002 — August, 2002

Method Leader on development of clinical immunochemical assays for cardiac markers on the Dimension instruments platform. • Served as R&D Project Leader on a cross-functional product development teams focused on validation of clinical assays in a GLP/ISO9001 environment. Made a major contribution to invention of new highly sensitive assays for adulteration of urine in analysis of drugs of abuse.

Research Scientist / April, 1999 — October, 2001

Principal investigator in Anti-Bacterial Department working on assay development for projects targeting protein synthesis, tRNA aminoacylation, cell-wall biosynthesis and DNA replication. • Developed and validated HTS-compatible assays for inhibition of protein synthesis in bacteria based on the in vitro transcription/translation of the firefly luciferase reporter gene. • Established assays for inhibition of bacterial aminoacyl-tRNA synthetases (AARS) by monitoring aminoacylation status of individual tRNA’s in bacterial cells by Northern blot analysis.

Associate Director / September, 2017 — May, 2020

Principal Scientist in R&D Department working on in vitro pharmacology, transporter assays, in vitro dissolution-absorption system, cell lines for assessing DDI of drug candidates. Assay development and implementation for gene and cell therapy products aimed at evaluation of their potency, transduction efficiency and establishing efficacy in vitro.

Director of Biology / June, 2020 — December, 2023

Oversaw Biology operations on several drug discovery programs in oncology. Partnered biochemistry and cell biology efforts with multiple CROs in the US and overseas. Responsible for establishing centralized database and data management/presentation. Outsourcing in vitro and in vivo pharmacology studies and data analysis.

Associate Director / January, 2017 — March, 2017

Following acquisition of Vitae Pharmaceuticals by Allergan and closing Vitae's site in Fort Washington, PA, I was responsible for transfer of scientific results, data, cell lines, reagents and equipment to Allergan.